Skip to main content
TipRanks
Go Ultimate75% OFF

Anebulo Pharmaceuticals (ANEB) AI Stock Analysis

37 Followers
ANEB

Anebulo Pharmaceuticals

(Other OTC:ANEB)

Select Model
Rating:33Underperform
Price Target:$0.30â–²(16.15% Upside)
Action:reiterated
Date:07/23/26

ANEB scores near the bottom of the range, driven primarily by severely bearish technicals and weak financial fundamentals. The stock is in a pronounced downtrend, trading at a fraction of its 200-day moving average with oversold but still deteriorating momentum indicators. Financially, the company generates no revenue, burns cash at ~$5.8M annually, and faces an eroding equity base that will likely necessitate dilutive capital raises. The debt-free balance sheet and moderating burn rate provide modest positives, but these are insufficient to offset the lack of revenue, clinical-stage risk, and persistent price deterioration. Valuation offers limited insight given the pre-commercial stage. This is a high-risk, speculative investment entirely dependent on clinical pipeline outcomes and future financing.

Positive Factors
Zero debt and positive equityZero interest-bearing debt and positive shareholder equity (~$7.9M) materially reduce refinancing and interest-rate risk. For a clinical-stage biotech this durable balance-sheet position preserves financial flexibility, extending runway and giving management time to reach clinical milestones before forced restructuring.
Negative Factors
Pre-revenue with persistent net lossesAnebulo remains pre-revenue with TTM net losses near -$8.0M, which limits visibility into future margins and commercial viability. This structural profile forces ongoing reliance on external capital, increases dilution risk, and means value realization depends heavily on successful clinical/regulatory milestones rather than operating cash flow.

Anebulo Pharmaceuticals (ANEB) vs. SPDR S&P 500 ETF (SPY)

-100%-75%-50%-25%0%25%ANEB-88.65%SPY+12.87%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$10.60M
Dividend Yield
―
Average Volume (3M)
466
Price to Earnings (P/E)
-1.7
Beta (1Y)
-116.56
Revenue Growth
―
EPS Growth
33.15%
Country
US
Employees
3
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

Anebulo Pharmaceuticals Business Overview & Revenue Model

Company Description

Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing treatments for unintentional cannabis poisoning, acute cannabinoid intoxication, and acute cannabis-induced conditions in the United States. The company’s le...

How the Company Makes Money

null

Anebulo Pharmaceuticals Financial Statement Overview

Summary

Anebulo Pharmaceuticals is a pre-revenue clinical-stage biotech with zero revenue, consistent net losses (~$8M TTM), and deeply negative returns on equity. Positives include a debt-free balance sheet and a moderating cash burn rate (operating cash outflow improved to $5.8M TTM from $9.7M in FY2023). However, stockholders' equity has eroded from $21.4M to $7.9M, raising runway concerns. The income statement score of 15, balance sheet score of 45, and cash flow score of 20 collectively reflect a fragile but not immediately critical financial position, contingent on future capital raises and clinical success.

Income Statement

15Very Negative

Balance Sheet

45Neutral

Cash Flow

20Very Negative
Financial statement breakdown
BreakdownTTMJun 2025Jun 2024Jun 2023Jun 2022Jun 2021
Income Statement
Total Revenue000000
Gross Profit000000
EBITDA-7.42M-7.72M-7.90M-11.73M-6.83M-30.24M
Net Income-7.98M-8.48M-8.20M-11.73M-6.83M-30.25M
Balance Sheet
Total Assets9.42M12.15M4.07M11.67M15.58M21.65M
Cash, Cash Equivalents and Short-Term Investments9.04M11.63M3.09M11.25M14.55M19.99M
Total Debt000000
Total Liabilities1.49M487.69K260.58K1.07M512.53K241.63K
Stockholders Equity7.94M11.66M3.81M10.60M15.07M21.41M
Cash Flow
Free Cash Flow-5.84M-6.35M-8.09M-9.68M-5.44M-4.87M
Operating Cash Flow-5.84M-6.35M-8.09M-9.68M-5.44M-4.87M
Investing Cash Flow000000
Financing Cash Flow-116.66K14.88M-62.35K6.38M021.83M

Anebulo Pharmaceuticals Technical Analysis

Technical Analysis SentimentNegative
Last Price0.26

Price Trends

50DMA0.31Negative
100DMA0.33Negative
200DMA0.47Negative

Market Momentum

MACD-0.01Negative
RSI42.71Neutral
STOCH91.93Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ANEB, the sentiment is Negative. The current price of 0.26 is below the 20-day moving average (MA) of 0.27, below the 50-day MA of 0.31, and below the 200-day MA of 0.47, indicating a bearish trend. The MACD of -0.01 indicates Negative momentum. The RSI at 42.71 is Neutral, neither overbought nor oversold. The STOCH value of 91.93 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ANEB.

Anebulo Pharmaceuticals Risk Analysis

Anebulo Pharmaceuticals disclosed 49 risk factors in its most recent earnings report. Anebulo Pharmaceuticals reported the most risks in the "Finance & Corporate" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

3 New Risks
1.Inadequate funding for the FDA, the SEC and other government agencies, including from government shutdowns, or other disruptions to these agencies' staffing and operations, could hinder their ability to hire and retain key leadership and other personnel, prevent new products and services from being developed or commercialized in a timely manner or otherwise prevent those agencies from performing normal business functions on which the operation of our business may rely, which could negatively impact our business.Q4, 2025
2.A shutdown of the U.S. federal government may adversely affect our business.Q4, 2025
3.A shutdown of the U.S. federal government may adversely affect our business.Q3, 2025

Anebulo Pharmaceuticals Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

ANEB against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
PTNPTN46Neutral$10.91M-1.15-115.00%―-46.89%55.46%
CTXRCTXR43Neutral$14.48M-0.25-67.15%――57.48%
KALAKALA41Neutral$2.47M-0.00-222.32%――78.25%
TPSTTPST40Underperform$6.83M-0.09-3552.74%――61.31%
ANEBANEB33Underperform$10.60M-1.69-64.46%――33.15%
PHIOPHIO30Underperform$8.99M-0.59-101.48%――43.66%

* Healthcare Sector Average

Performance Comparison

-100%-50%0%50%100%ANEBPTNTPSTPHIOKALACTXRDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
ANEB and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
ANEBAnebulo Pharmaceuticals, Inc.0.26-2.04-88.70%
PTNPalatin Technologies, Inc.6.13-7.68-55.62%
TPSTTempest Therapeutics, Inc.0.34-4.41-92.82%
PHIOPhio Pharmaceuticals0.75-0.50-39.84%
KALAKala Bio, Inc.3.83-945.67-99.60%
CTXRCitius Pharma0.53-0.47-47.30%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Jul 23, 2026